within Pharmacolibrary.Drugs.ATC.N;

model N04BX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 10.833333333333334,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00795,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), used as an adjunct to levodopa/carbidopa therapy in the management of Parkinson's disease. It is approved and widely used today to prolong the effect of levodopa by blocking its peripheral degradation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after a single oral 200 mg dose.</p><h4>References</h4><ol><li>Thomas MÃ¼ller,Entacapone.,Expert opinion on drug metabolism & toxicology,2010<a href='https://pubmed.ncbi.nlm.nih.gov/20572781/'>https://pubmed.ncbi.nlm.nih.gov/20572781/</a></li><li>Robert A Hauser,Levodopa/carbidopa/entacapone (Stalevo).,Neurology,2004<a href='https://pubmed.ncbi.nlm.nih.gov/14718682/'>https://pubmed.ncbi.nlm.nih.gov/14718682/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N04BX02;
